Duplicate marketing authorisation: second authorisation for the same medicine
A duplicate marketing authorisation is a second authorisation for the same medicine, held by the same or a linked company, usually under another name.
Also known as: duplicate MA, duplicate application, multiple application, duplicate marketing authorization
3 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Article 82(1), Regulation (EC) No 726/2004, for centralised products
- Allowed for
- Public health reasons on availability, or co-marketing
- Who decides
- The European Commission, before the application goes to EMA
- National route
- Parallel applications in the same MRP or DCP
How it works
A duplicate is an authorisation for a product that is the same as one already authorised or applied for: the same qualitative and quantitative composition in active substances and the same pharmaceutical form, supported by the same dossier, but with a different invented name and often a different holder, such as another company in the group or a licensing partner. For centrally authorised products the starting point is a prohibition. Article 82(1) of Regulation (EC) No 726/2004 provides that only one authorisation may be granted to an applicant for a specific medicinal product. The Commission must nevertheless authorise the same applicant to submit more than one application to EMA where there are objective verifiable reasons relating to public health regarding the availability of medicinal products to healthcare professionals or patients, or for co-marketing reasons.
In practice the applicant asks the Commission before submitting to EMA, states which of the two grounds applies and provides the evidence. The Commission's note on the handling of duplicate marketing authorisation applications sets out how it reads the grounds. The note was updated in 2021 and treats duplicates as an exception: the Commission looks for evidence that the second authorisation will in fact improve availability, or that a separate company will co-market the product. Once the Commission agrees, the duplicate application is submitted and assessed like any other. It receives its own Commission decision, its own number in the Union Register and its own invented name, which goes through EMA's name review separately.
Directive 2001/83/EC contains no equivalent prohibition, so duplicates of national authorisations are common. In a mutual recognition or decentralised procedure the applicant files two or more identical applications in parallel, under different names or for different holders, with the same reference member state, and the CMDh has published recommendations on handling these multiple applications. Typical reasons are co-marketing with a local partner, a branded and an unbranded version of the same generic, and a second brand name where the first is not acceptable in every country.
Each duplicate is a full authorisation with its own lifecycle. Every variation, renewal, safety reporting obligation and fee applies to each one, and the dossiers have to be kept identical for as long as the products are meant to be the same. Where the holders are linked, a duplicate belongs to the same global marketing authorisation as the original, so it brings no new data exclusivity.
What goes wrong
A centralised duplicate applied for without the Commission's prior agreement, or on grounds the Commission does not accept; a variation filed for the original and forgotten for the duplicate, so the two product information texts diverge; a duplicate that is never marketed and lapses under the sunset clause; and fees underestimated because each duplicate is charged separately at application and throughout its life. Companies also overlook that a duplicate created for a licensing partner has to be transferred or withdrawn in an orderly way when the partnership ends.
Timing
The Commission's agreement is needed before a centralised duplicate is submitted, so the request is made well ahead of the planned submission date. The duplicate application then follows the normal timetable of its procedure. National duplicates filed in parallel with the original application run on the same timetable as the original.
Duplicate marketing authorisation: common questions
What is a duplicate marketing authorisation?
It is a second, separate marketing authorisation for a medicine that is identical to one already authorised or applied for, with the same composition, pharmaceutical form and dossier. It usually carries a different invented name and may be held by another company in the group or by a licensing partner.
When does the Commission allow a duplicate of a centrally authorised product?
Article 82(1) of Regulation (EC) No 726/2004 allows one authorisation per applicant and product, with two exceptions: objective verifiable reasons relating to public health regarding the availability of the medicine to healthcare professionals or patients, and co-marketing reasons. The applicant must obtain the Commission's agreement, with supporting evidence, before submitting the duplicate application to EMA.
Does a duplicate marketing authorisation need its own variations and fees?
Yes. A duplicate is an independent authorisation. Each variation, renewal and safety obligation has to be met for the original and for the duplicate, each with its own fee, and the two dossiers must be kept aligned. A duplicate that is not marketed for three consecutive years lapses under the sunset clause like any other authorisation.